Department of Health
and Human Services (HHS)
and Human Services (HHS)
August 10, 2020
RFA-DA-21-005 - Exploiting in vivo or in situ imaging approaches to understand HIV-relevant processes in the context of substance use disorders (R61/R33 Clinical Trials Optional)
National Institute on Drug Abuse (NIDA)
This Notice informs interested applicants that funding opportunity announcement RFA-DA-21-005 "Exploiting in vivo or in situ imaging approaches to understand HIV-relevant processes in the context of substance use disorders (R61/R33 Clinical Trials Optional)" has been amended to add an additional submission date.
The FOA has been modified as follows:
Currently Reads:
Part 1. Overview Information, Key Dates
Open Date (Earliest Submission Date): July 13, 2020
Letter of Intent Due Date(s): July 13, 2020
Application Due Date(s): Only accepting applications for the AIDS Application Due Date(s) listed below.
All applications are due by 5:00 PM local time of applicant organization. All types of AIDS and AIDS-related applications allowed for this funding opportunity announcement are due on the listed date(s).
Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
AIDS Application Due Date(s): August 13, 2020
All applications are due by 5:00 PM local time of applicant organization. All types of AIDS and AIDS-related applications for this funding opportunity announcement are due on the listed date(s).
Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
Scientific Merit Review: November 2020
Advisory Council Review: January 2021
Earliest Start Date: April 2021
Expiration date:August 14, 2020
Part 2, Full Text of Announcement, Section II Award information
Application types allowed: New
Funds Available and Anticipated Number of Awards NIDA intends to commit $3 M in FY2021 to fund 5-8 awards.
Section V. Application Review Information, Additional Review Criteria
Resubmission Not applicable.
Revised to Read:
Part 1. Overview Information, Key Dates
Open Date (Earliest Submission Date): July 13, 2020
Letter of Intent Due Date(s): July 13, 2020, July 13, 2021
Application Due Date(s): Only accepting applications for the AIDS Application Due Date(s) listed below.
AIDS Application Due Date(s): August 13, 2020, August 13, 2021
All applications are due by 5:00 PM local time of applicant organization. All types of AIDS and AIDS-related applications for this funding opportunity announcement are due on the listed date(s).
Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
Scientific Merit Review: November 2020, November 2021
Advisory Council Review: January 2021, January 2022
Earliest Start Date: April 2021
Expiration date: August 14, 2021
Part 2, Full Text of Announcement, Section II Award information
Application types allowed New, Resubmission
Funds Available and Anticipated Number of Awards NIDA intends to commit $3 M in FY2021 to fund 5-8 awards. NIDA intends to commit $3 M in FY2022 to fund 5-8 awards.
Section V. Application Review Information, Additional Review Criteria
Resubmission For Resubmissions, the committee will evaluate the application as now presented, taking into consideration the responses to comments from the previous scientific review group and changes made to the project.
All other aspects of this FOA remain unchanged.
Vasundhara Varthakavi, DVM, PhD
National Institute on Drug Abuse (NIDA)
Telephone: 301-443-2146
Email: vasundhara.varthakavi@nih.gov
John Satterlee Ph.D.
National Institute on Drug Abuse (NIDA)
Telephone: 301-435-1020
Email: satterleej@nida.nih.gov